( 1 ) doxorubicin and paclitaxel , in the doses used here , have equivalent activity ; ( 2 ) the combination of AT results in superior overall response rates and time to TTF ; and ( 3 ) despite these results , combination therapy with AT did not improve either survival or quality of life compared to sequential single-agent therapy .
